Enveric

A conversation with Joseph Tucker, Ph.D., CEO, Enveric Biosciences Non-hallucinogenic neuroplastogens are being developed as a potentially safer alternative to psychedelics, with a lower risk of hallucinations. Enveric Biosciences is…

In biotech, competitive lines are often drawn in the lab. Increasingly, they are drawn in patent court. This week, Enveric Biosciences announced that a Post Grant Review petition filed against…

Enveric Biosciences Inc. (NASDAQ:ENVB) on Wednesday said that the previously announced Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals Inc. against Enveric's issued U.S. Patent No. 12,138,276 (the '276 patent)…

In a development that could ripple across the fast evolving neuroplastogen sector, Enveric Biosciences announced that a Post Grant Review petition filed against one of its key U.S. patents has…

Enveric Biosciences reported new mechanistic data showing that its lead neuropsychiatric candidate EB-003 engages both Gq and β-arrestin signaling downstream of the 5-HT2A receptor, based on proprietary bioluminescence resonance energy…

For much of the past decade, the psychedelic renaissance has revolved around experience. Carefully supervised psilocybin sessions. Structured integration. Regulatory pathways built around high-touch therapeutic models. But beneath that narrative,…

Enveric Biosciences (NASDAQ:ENVB) stock surged 13.4% in premarket trading Thursday after the company announced new mechanistic data for its lead drug candidate EB-003, demonstrating the compound’s activation of dual signaling…

In a sector often driven by clinical headlines, Enveric Biosciences has shifted attention back to the molecular level. The company today released new mechanistic data on its lead candidate, EB-003,…

Enveric Biosciences (NASDAQ:ENVB) on Thursday shared new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor. EB-003 is being developed…

For decades, psychedelics like psilocybin and N,N-dimethyltryptamine (DMT) have intrigued scientists and clinicians with their ability to rapidly reshape the brain and improve mental health. Clinical trials have shown promise…